Kumudu Pathiraja
About
Kumudu Pathiraja is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine.
According to data from OpenAlex, Kumudu Pathiraja has authored 36 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Kumudu Pathiraja's work include Cancer Immunotherapy and Biomarkers (23 papers), CAR-T cell therapy research (10 papers) and Lymphoma Diagnosis and Treatment (10 papers). Kumudu Pathiraja is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), CAR-T cell therapy research (10 papers) and Lymphoma Diagnosis and Treatment (10 papers). Kumudu Pathiraja collaborates with scholars based in United States, Israel and South Korea. Kumudu Pathiraja's co-authors include Shilpa Gupta, Ravit Geva, Jonathan D. Cheng, Raanan Berger, Laura Q.M. Chow, Vassiliki Karantza, Laurence Buisseret, Lajos Pusztai, Rita Nanda and Gursel Aktan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
Kumudu Pathiraja
34 papers receiving 3.3k citations
Hit Papers
Peers
Kumudu Pathiraja
Sanatan Saraf United States
Shunichi Okushiba Japan
Ani Sarkis Balmanoukian United States
Esma Saâda-Bouzid France
Mizutomo Azuma Japan
Ryosuke Okamura Japan
Yosuke Otake Japan
Tchao Méatchi France
T Kabuto Japan
Chan-Young Ock South Korea
Citations per year, relative to Kumudu Pathiraja Kumudu Pathiraja (= 1×)
peers
Sanatan Saraf
Countries citing papers authored by Kumudu Pathiraja
Since
Specialization
Citations
This map shows the geographic impact of Kumudu Pathiraja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kumudu Pathiraja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kumudu Pathiraja more than expected).
Fields of papers citing papers by Kumudu Pathiraja
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Kumudu Pathiraja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kumudu Pathiraja. The network helps show where Kumudu Pathiraja may publish in the future.
Co-authorship network of co-authors of Kumudu Pathiraja
This figure shows the co-authorship network connecting the top 25 collaborators of Kumudu Pathiraja. A scholar is included among the top collaborators of Kumudu Pathiraja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kumudu Pathiraja. Kumudu Pathiraja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Norasetthada, Lalita, Joaquín Borrego‐Díaz, Fangfang Lv, et al.. (2024). Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood. 144(Supplement 1). 1738–1738.
2.
Fosså, Alexander, Muhıt Özcan, Yuqin Song, et al.. (2023). WAVELINE‐004: OPEN‐LABEL, PHASE 2 STUDY OF ZILOVERTAMAB VEDOTIN (MK‐2140) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). Hematological Oncology. 41(S2). 208–209.
3.
Özcan, Muhıt, Yuqin Song, Seung‐Tae Lee, et al.. (2023). P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). HemaSphere. 7(S3). e03345ef–e03345ef.
4.
McDonald, Andrew, Estelle Verburgh, Manuel Gotti, et al.. (2023). Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL). Hematological Oncology. 41(S2). 575–577.
5.
Özcan, Muhıt, Fangfang Lv, Lalita Norasetthada, et al.. (2023). Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study. Blood. 142(Supplement 1). 1720–1720.
6.
McDonald, Andrew, Estelle Verburgh, Manuel Gotti, et al.. (2023). Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma. Blood. 142(Supplement 1). 4442–4442.
7.
Geoerger, Birgit, Hyoung Jin Kang, Michal Yalon-Oren, et al.. (2019). Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. The Lancet Oncology. 21(1). 121–133.
8.
Geoerger, Birgit, Hyoung Jin Kang, Michal Yalon-Oren, et al.. (2018). KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1–positive advanced, relapsed or refractory solid tumor or lymphoma.. Journal of Clinical Oncology. 36(15_suppl). 10525–10525.
9.
Mehra, Ranee, Tanguy Y. Seiwert, Shilpa Gupta, et al.. (2018). Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. British Journal of Cancer. 119(2). 153–159.
10.
Baselga, José, Serafín Morales, Ahmad Awada, et al.. (2017). A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. 163(3). 535–544.
11.
Muro, Kei, Hyun Cheol Chung, Veena Shankaran, et al.. (2016). Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. The Lancet Oncology. 17(6). 717–726.
12.
Chung, Hyun Cheol, Veena Shankaran, Ravit Geva, et al.. (2015). LBA-04 Clinical outcomes and their correlation with gene expression in patients with advanced gastric cancer treated with pembrolizumab (MK-3475): KEYNOTE-012. Annals of Oncology. 26. iv118–iv118.
13.
Chow, Laura Q.M., Ranee Mehra, Barbara Burtness, et al.. (2015). 2866 Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012. European Journal of Cancer. 51. S579–S579.
14.
Ghia, Paolo, et al.. (2015). A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib Compared to Ofatumumab in Patients with Refractory Chronic Lymphocytic Leukemia. Blood. 126(23). 4171–4171.
15.
Seiwert, Tanguy Y., Robert I. Haddad, Shilpa Gupta, et al.. (2015). Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.. Journal of Clinical Oncology. 33(18_suppl). LBA6008–LBA6008.
16.
O’Donnell, Peter H., Elizabeth R. Plimack, Joaquim Bellmunt, et al.. (2015). Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results of a phase IB study.. Journal of Clinical Oncology. 33(7_suppl). 296–296.
17.
Plimack, Elizabeth R., Joaquim Bellmunt, Shilpa Gupta, et al.. (2015). Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.. Journal of Clinical Oncology. 33(15_suppl). 4502–4502.
18.
Plimack, Elizabeth R., Shilpa Gupta, Joaquim Bellmunt, et al.. (2014). A Phase 1B Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Advanced Urothelial Tract Cancer. Annals of Oncology. 25. v1–v1.
19.
Chow, Laura Q.M., Barbara Burtness, Jared Weiss, et al.. (2014). A Phase Ib Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Human Papiilloma Virus (Hpv)-Positive and Negative Head and Neck Cancer (Hnc). Annals of Oncology. 25. v1–v1.
20.
Hochhauser, Daniel, Rob Glynne‐Jones, Vanessa Potter, et al.. (2013). A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of theO6-Methylguanine-DNA Methyltransferase Promoter. Molecular Cancer Therapeutics. 12(5). 809–818.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sanatan Saraf Breakdown of academic impact, for papers by Shunichi Okushiba Breakdown of academic impact, for papers by Ani Sarkis Balmanoukian Breakdown of academic impact, for papers by Esma Saâda-Bouzid Breakdown of academic impact, for papers by Mizutomo Azuma Breakdown of academic impact, for papers by Ryosuke Okamura Breakdown of academic impact, for papers by Yosuke Otake Breakdown of academic impact, for papers by Tchao Méatchi Breakdown of academic impact, for papers by T Kabuto Breakdown of academic impact, for papers by Chan-Young Ock